Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro

Thomas Klein,¹ Jens Benders,¹ Friederike Roth,¹ Monika Baudler,² Isabel Siegle,³ and Martin Kömhoff¹,4

¹Department of Pediatrics, Philipps University, 35033 Marburg, Germany
²F. Hoffmann-La Roche, 4070 Basel, Switzerland
³Dr. Margarete Fischer Bosch Institute for Clinical Pharmacology, 70376 Stuttgart, Germany
⁴University Medical Center Groningen, 9700 RB Groningen, Netherlands

Correspondence should be addressed to Martin Kömhoff; m.komhoff@umcg.nl

Received 1 April 2015; Revised 8 June 2015; Accepted 1 July 2015

Academic Editor: Marc Pouliot

Copyright © 2015 Thomas Klein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Endogenously formed prostacyclin (PGI₂) and synthetic PGI₂ analogues have recently been shown to regulate cell survival in various cell lines. To elucidate the significance of PGI₂ in human breast cancer, we performed immunohistochemistry to analyze expression of prostacyclin-synthase (PGIS) in 248 human breast cancer specimens obtained from surgical pathology files. We examined patients’ 10-year survival retrospectively by sending a questionnaire to their general practitioners and performed univariate analysis to determine whether PGIS expression correlated with patient survival. Lastly, the effects of PGI₂ and its analogues on cell death were examined in a human breast cancer cell line (MCF-7) and a human T-cell leukemia cell line (CCRF-CEM). PGIS expression was observed in tumor cells in 48.7% of samples and was associated with a statistically significant reduction in 10-year survival \( P = 0.038; n = 193 \). Transient transfection of PGIS into MCF-7 cells exposed to sulindac increased cell viability by 50% and exposure to carbaprostacyclin protected against sulindac sulfone induced apoptosis in CCRF-CEM cells. Expression of PGIS is correlated with a reduced patient survival and protects against cell death in vitro, suggesting that PGIS is a potential therapeutic target in breast cancer.

1. Introduction

Epidemiological studies have shown that regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of a range of epithelium-derived malignancies [1]. NSAIDs inhibit the enzymatic activity of cyclooxygenase (COX), the enzyme that provides prostaglandin H₂ (precursor to prostacyclin [PGI₂]) and is therefore considered to provide the rate-limiting step during prostanoid synthesis [2]. Two isoforms exist: the constitutive COX-1 and the inducible COX-2. Specific inhibitors of the latter (also called coxibs or COX-2 selective NSAIDs) have been developed because gastrointestinal side-effects of NSAIDs are thought to result from COX-1 inhibition. As COX-2 is expressed in the majority of human cancers, including breast cancer [3, 4], COX-2 selective inhibitors (coxibs) next to COX-2 unselective ones (conventional NSAID) are tested for their antitumor activity.

The most significant effects of NSAIDs have been observed in cancers of the digestive tract, including the colon [5]. The potential effect of NSAIDs in the chemoprevention of breast cancer is being investigated; however, current understanding is less clear than in colon cancer. A study in rats found a reduced relative risk of breast cancer associated with the use of coxib celecoxib [6]. Results in women are conflicting: a cohort study in women, which analyzed the incidence of breast cancer, did not find a protective effect linked to the intake of aspirin [7]. A beneficial effect of NSAIDs on the incidence of breast cancer has however been demonstrated in recent meta-analyses [8–10]. In vitro,
incubation of NSAIDs with human breast cancer cell lines has been shown to induce apoptosis [11]. In contrast to the extensively studied function of COX-2 in tumor formation, little information exists on the role of prostanoid forming enzymes and receptors acting downstream of COX. Prostacyclin-synthese (PGIS) has recently been implicated in the regulation of cell survival and induction of NSAID-mediated cell death in HT29 colon cancer cells can be abrogated by the addition of carbasprostacyclin, a synthetic analogue of PGI₂ [12]. When exposed to hypertonic stress, cell death in rabbit renal cells was significantly reduced by addition of carbasprostacyclin but not by other prostanoids [13]. In contrast, overexpression of PGIS, as well as exogenously added carbasprostacyclin, induces apoptosis in human embryonic kidney cells (HEK293) [14]. Prostacyclin activates the adenylate cyclase coupling prostacyclin-receptor (IP), which mediates the anti-aggregatory effect of PGI₂ on platelets as well as its vasodilatory action on smooth muscle cells [15]. However, the effects of PGI₂ on cell survival are independent of cyclic adenosine monophosphate (cAMP) generation and thus activation of IP. Mounting evidence suggests that PGI₂ can activate the nuclear transcription factor peroxisome proliferator activated receptor β/δ (PPAR β/δ). Various fatty acids including carbasprostacyclin have been suggested to activate PPAR β/δ [16]. Activation of PPAR β/δ-reporter plasmids by cotransfection of PGIS indicate that, in addition to carbasprostacyclin, endogenously formed PGI₂ may also be a ligand for PPAR β/δ [14, 17]. However, in a more recent study, endogenous PGI₂ was not confirmed as a PPAR β/δ agonist [18]. Taken together, previous studies suggest that PGIS can regulate cell survival possibly by activation of PPAR β/δ. Therefore, that PGIS could be a target in tumor biology.

In order to elucidate a potential role of PGIS in breast cancer, we analyzed the expression of this enzyme in human breast cancer and retrospectively examined its effect on patient survival. Furthermore, the effect of overexpressing PGIS on NSAID-induced cell death was studied in a breast cancer cell line (MCF-7); and the effect of the synthetic analogue carbasprostacyclin was tested similarly in a human T-cell leukemia cell line (CCRF-CEM).

2. Materials and Methods

2.1. Case Selection and Histopathology. Cases of patients with breast cancer (n = 248, surgery performed 1986–1990) were retrieved from the surgical pathology files of the Robert Bosch Krankenhaus (Stuttgart, Germany) and followed up with a questionnaire sent to their general practitioner. The drop-out rate was 55 patients (22.1%) without further selection or bias in the remaining 193 cases. The mean follow-up time was 67.4 months (median: 55 months [range: 1–119]). Tumor staging was performed according to World Health Organization guidelines [19]. All patients had initially undergone either mastectomy surgery or a breast-conserving resection of their primary carcinomas. We discriminated ductal invasive carcinoma (78.2%), lobular invasive carcinoma (8.8%), and invasive carcinoma specified otherwise (13.0%). Estrogen and progesterone receptor expression was analyzed biochemically with charcoal and dextran using 20 fmol/mg protein as cutoff point [20]. In addition to reviewing pathology reports, slides of all cases were reexamined for uniform assignment of grade and stage and other histopathologic features. Only the invasive tumor component was considered for evaluation.

2.2. Immunohistochemistry. Sections were cut (3 μm thickness), deparaffinized in xylene, and incubated for 30 minutes in methanol containing 0.3% H₂O₂ to block endogenous peroxidase activity. Sections were then incubated with rabbit anti-PGIS polyclonal antibodies, as described previously [21]. Briefly, sections were microwaved in phosphate buffered saline (PBS) containing 0.1 M sodium citrate and primary antibodies were incubated overnight at room temperature. Immunolabeling was detected using a biotinylated rabbit anti-goat antibody followed by visualization with an avidin-biotin horseradish peroxidase labeling kit (Vectastain ABC kit) and dianinobenzidine staining. The specificity of the polyclonal antibodies for PGIS used in this study has been extensively characterized in our previous study analyzing routinely formalin fixed human tissue cut in serial sections where identical staining patterns could be demonstrated for PGIS immunoreactive protein and mRNA using immunohistochemistry and radioactive in situ hybridization (ISH), respectively [21]. Expression of PGIS immunoreactive protein in human breast cancer samples was analyzed independently by two investigators who were blinded to patient data. In tumor tissues, staining intensity was scored visually as absent (0), weak (1), moderate (2), or strong (3). The percentage of PGIS-positive tumor cells was graded as absent (0), 1% to 10 (1), 11% to 50% (2), 51% to 80% (3), and 81% or more (4). The immunoreactive score (IRS) index was calculated as the product of the two values [22]. Photomicrographs were viewed with a Leitz RMB microscope and pictures were captured with a digital camera (Spot-Cam, Diagnostic Instruments, Sterling Heights, MI). Color composites were generated by using Adobe Photoshop v5.0 on a Power Macintosh.

2.3. Cell Culture. MCF-7 human breast carcinoma cells and CCRF-cells were obtained from DMSZ (Hannover, Germany). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) tissue culture medium supplemented with 10% (v/v) fetal bovine serum (FBS) and streptomycin and penicillin. CCRF-cells were grown in Roswell Park Memorial Institute (RPMI) medium 10% FBS supplemented with gentamycin. Cultures were incubated at 37°C in 95% O₂ and 5% CO₂. Tissue culture medium was changed every 48–72 hours.

2.4. Generation and Functional Characterization of a Prostacyclin-Synthese Expression Vector. A murine full length PGIS cDNA was amplified from total neonatal kidney cDNA using Advantage two-step polymerase chain reaction (Clontech, CA). The PGIS upstream primer was 5’CTTGTTGCCACCCCTGAGCC 3’, and the downstream primer was 5’CAGGAAGTCAGAGGGCCC 3’. DNA-fragments were cloned into pcDNA3.1 expression vector (Invitrogen, NL) to yield pCDNA3.1mPGIS. An enzymatically
inactive mutant of mPGIS (PGIS C441A) was prepared by site directed mutagenesis (QuikChange, Stratagene, CA) according to Hatae and coworkers [23]. Oligonucleotide primers used to prepare the mutants were 5’-AGG GCA CAA CCA GAG CCT GGG GAA GAG TTA TGC C-3’ and 5’-GGC ATA ACT CTT CCC CAG GCA CTG GTT GTG CCC T-3’. Expression of wild-type and mutant PGIS was analyzed by Western blot analysis using the same rabbit polyclonal antibodies as for the immunohistochemical analysis as described previously [24]. Briefly, 20 μg of total cell lysates was harvested 48 hours after transfection, separated on 10% SDS-PAGE, blotted onto nitrocellulose, and probed with the rabbit polyclonal anti-PGIS antibodies (diluted 1:500). Enzymatic activity of wild-type PGIS protein was shown by detection of 6-keto-prostaglandin F1α (6-keto-PGF1α), the stable metabolite of PGI2, by gas-chromatography/mass spectrometry (GC/MS) in supernatants from transfected cells, as described previously [25]. Cotransfection for 48 hours of a COX-2 expression vector (pCDNA3.1COX-2, kindly provided by Dr. Guan et al. [26], with pCDNA3.1mPGIS (wild-type PGIS)) into MCF-7 cells resulted in abundant generation of 6-keto-PGF1α (1.48 ± 0.286 ng/mL of supernatant). No significant generation of 6-keto-PGF1α was observed in MCF-7 cells coexpressing pCDNA3.1COX-2 with either pCDNA3.1 or pCDNA3.1mPGISC441A (0.03 ± 0.009 and 0.0023 ± 0.01 6-keto-PGF1α ng/mL, resp.).

## 2.5. Transfection of cDNA and Experimental Design.

All plasmid-mediated transfections were performed on 40–60% confluent cells using Polyfect (Qiagen, Germany). pCDNA3.1mPGIS and pCDNA3.1COX-2 (2 μg each) were transfected into 6-well dishes. Cells were then transferred to DMEM medium supplemented with 0.5% (v/v) FBS for 24 hours and exposed to 150 μM sulindac and sulindac sulfone for additional 24 hours. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

The effect of the stable PGI2 analogue caraprostacyclin on cell viability was analyzed in CCRF-CEM cells exposed to sulindac sulfone. Cells were grown in RPMI supplemented with 10% (v/v) FBS and gentamycin. CCRF-CEM cells were coincubated for 48 hours with sulindac sulfone (100 and 300 μM) and either vehicle, increasing concentrations of caraprostacyclin (0.01–1 μM), or the membrane permeable cAMP analogue dibutyryl-cAMP (dbcAMP, 0.001–10 mM). Apoptotic cell death was analyzed by measuring caspase-3 activity as assessed by cleavage of Ac-DEVD-AMC fluorogenic substrate (Pharmingen, CA).

## 2.6. Statistical Methods.

Patient data assessments were conducted using SPSS (SPSS Software GmbH, Munich, Germany). Survival curves were established according to the Kaplan-Meier method, and comparisons between survival curves were performed with the log-rank test. Overall survival was calculated from the date of surgery to death or to the date of the last patient contact. Disease-free survival was measured from the date of surgery until the time of relapse, cancer-related death, or last contact. Patients who died from unrelated causes were considered censored by the time of their death. To define a cutoff point for PGIS expression, the minimal P value approach was applied. The IRS ≥ 3 was used for all further analyses. Multivariate analyses were performed using Cox regression analysis in a model with T, N, M, G, and ER and PR status. Association between PGIS expression and other parameters such as age, tumor size, nodal status, and hormonal status was assessed by the test.

Cell culture experiments were analyzed with Student’s t-test.

## 3. Results

### 3.1. Expression of Prostacyclin-Synthase in MCF-7 Cells.

To confirm expression of wild-type and mutant PGIS protein, Western blot analysis was performed using MCF-7 cell lysates (20 μg per lane). In Figure 1(a), a band could not be detected in cells transfected with the control vector pCDNA 3.1 (lane 1). Bands of approximately 52 kD corresponding to the molecular weight of PGIS could be detected in cells transfected with both the PGIS wild-type...
3.2. Expression of Prostacyclin-Synthase in Breast Cancer Tissue. Expression of PGIS immunoreactive (ir) protein was examined in tumor samples from 248 patients with breast cancer obtained at diagnosis of primary breast cancer disease. Patient age was 26–86 years; median (±SD) age was 56.49 ± 12.11 years. PGIS-immunoreactivity in tumor cells was observed in 48.7% of samples and was generally weak in tumor cells. In PGIS-positive tumor cells, cytoplasm and perinuclear staining was observed consistent with the expression of PGIS in the endoplasmic reticulum and the perinuclear envelope [27]. Expression of PGIS ir-protein in tumor cells differed in both staining intensity and percentage of positive tumor cells (Figures 1(b) and 1(c)). PGIS-immunoreactivity was also observed in various cell samples known to express this enzyme (fibroblasts: 68%; inflammatory cells: 62.2%; and vessels 61.7%; data not shown).

3.3. Univariate Analysis. Kaplan-Meier survival curves were created from the data of 193 patients with complete information (see Table 1) to evaluate the prognostic value of established parameters for overall survival. As expected, the classical prognostic factors, that is, histology grade, tumor size, and nodal status, were all significantly associated with overall survival, whereas age, steroid receptor status, and menopausal age were not (Table 1). To evaluate a possible relationship between PGIS expression and disease outcome, different IRS subgroups were initially defined and Kaplan-Meier analysis was performed for overall survival. In these analyses, it became apparent that subgroups with higher PGIS expression levels had shorter mean survival times than subgroups with lower expression (data not shown). This suggested the use of a single cutoff value to simplify further analyses. To select a value, the minimal $P$ value

### Table 1: Statistics on Patients’ Clinical Data, Classical Prognostic Factors, and PGIS Expression ($n = 193$).

| Parameter            | $N$ (193) | IRS: 0–2 (Patients $N$) | PGIS expression | IRS: 3–12 (Patients $N$) | $P$   |
|----------------------|-----------|-------------------------|-----------------|-------------------------|-------|
| Median age, years    | 54        | 83/110                  | 0.127*          | 20.5%                   | 0.05**|
| Age </> median       |           |                         |                 |                         |       |
| < 56 years           | 83        | 66                      | 79.5            | 17                      | 20.5% |
| > 56 years           | 110       | 84                      | 76.4            | 54                      | 23.6% |
| Menopausal status    | 56        | 37/100/56               | 0.715*          |                         |       |
| Premenopausal        | 37        | 30                      | 81.1            | 7                       | 18.9% |
| Postmenopausal       | 100       | 81                      | 81.0            | 19                      | 19.0% |
| Tumor size           |           |                         |                 |                         |       |
| < 2 cm               | 45        | 39                      | 86.7            | 6                       | 13.3% |
| > 2 cm               | 144       | 109                     | 75.7            | 35                      | 24.3% |
| Nodal status         | 3         | 80/92/13/5/3            | <0.0001*        |                         |       |
| N0/N1/N2/N3/?        | 80        | 63                      | 78.8            | 17                      | 21.3% |
| N1–N3 node positive  | 110       | 85                      | 77.3            | 25                      | 22.7% |
| Grading              | 4         | 8/122/59/4              | 0.0402*         |                         |       |
| G1/G2/G3/?           | 4         | 130                     | 83.1            | 22                      | 16.9% |
| G1 & G2              | 59        | 39                      | 66.1            | 20                      | 33.9% |
| ER/PR                |           |                         |                 |                         |       |
| +++/++--/+--/+--/+--/ | 96/30      | 78/8                    | 81.2            | 18                      | 18.8% |
| Pos/pos              | 30        | 20                      | 66.6            | 10                      | 33.3% |
| Pos/neg or neg/pos   | 57        | 43                      | 75.4            | 14                      | 24.6% |

PGIS = prostacyclinsynthase; IRS = immunoreactive score; IRS 0–2 = low PGIS expression; IRS 3–12 = high PGIS expression; $N =$ number; cm = centimeter; ER = estrogen receptor; PR = progesterone receptor; pos = positive; neg = negative.

* $P$ value for overall survival (log-rank test).

** $P$ value for expression of PGIS ($\chi^2$ test).
approach was used, and cutoffs from IRS 1 to 5 were compared by Kaplan-Meier analysis. The statistical results, with and without application of the Bonferroni correction for multiple statistical testing, are listed in Table 2. The most discriminative value (IRS ≥ 3) was used for further subgroup analyses and multivariate Cox regression analysis. At 10 years following their diagnosis, 64.6% of patients with low PGIS expression (IRS < 3) were still alive compared with 36.4% in the group with high PGIS expression (IRS ≥ 3, Figure 2).

Table 2: Kaplan-Meier overall survival analysis for different immunoreactive scores.

| Cutoff (IRS) | Number | Overall survival prognosis |
|-------------|--------|---------------------------|
| ≥ 1         | 99/94  | 5.56 0.0184                |
| ≥ 2         | 129/64 | 4.37 0.0377                |
| ≥ 3         | 150/43 | 8.37 0.0038                |
| ≥ 4         | 161/32 | 6.35 0.0117                |
| ≥ 5         | 177/16 | 4.50 0.0338                |

IRS = immunoreactive score, * Bonferroni correction for multiple testing.

Figure 2: Relationship between PGIS expression and overall survival of 193 patients. The Kaplan-Meier survival curves shown are for subgroups with either low (IRS2) or high (IRS ≥ 3) PGIS expression among all patients under study.

3.4. Multivariate Analysis. On multivariate Cox analysis, the following factors were tested: tumor size, nodal status, tumor grading, and PGIS expression (cutoff IRS ≥ 3). In this model, PGIS expression did not prove to be an independent prognostic factor.

3.5. Overexpression of PGIS in MCF-7 Cells. The role of PGIS in the protection against NSAID-induced cell death was examined in human MCF-7 breast cancer cells. In vehicle-treated (0.1% DMSO) cells viability was not affected by transfection with wild-type or mutant PGIS vector (compared to control vector, data not shown). Upon exposure to sulindac (150 μM) for 24 hours, the viability of cells transfected with control vector and cells transfected with mutant PGIS was significantly reduced compared with MCF-7 cells transfected with wild-type PGIS as assessed by the MTT assay (mock: 0.153 ± 0.19 and PGISC441A: 0.2065 ± 0.038 compared with wild-type PGIS: 0.312 ± 0.048 optical density 540 nm/690 nm). In contrast to mock- and pCDNA3.1PGISC441A-transfected cells, overexpression of wild-type PGIS also increased cell viability in MCF-7 cells exposed to 150 μM sulindac sulfone compared with, albeit to a lesser extent than with, sulindac (data not shown).

3.6. Effect of Carbaprostacyclin on Cell Viability in CCRF-Cells. Exposure of CCRF-CEM cells to 100 and 300 μM sulindac sulfone induced apoptotic cell death in a dose-dependent manner as analyzed by measurement of caspase-3 activity (Figure 3(b)). Coincubation of CCRF-CEM cells with sulindac sulfone and increasing concentrations of carbaprostacyclin (0.01–1 μM) resulted in a decrease of apoptotic cells by about 50% at either sulindac sulfone concentration and by carbaprostacyclin 1 μM. Thus, treatment with the synthetic PG1 analogue carbaprostacyclin protected against NSAID-induced apoptosis. Cells were coincubated with sulindac sulfone and the membrane permeable cAMP analogue dibutyryl-cAMP (dbcAMP) to rule out involvement of the classical prostacyclin-receptor IP in protection against apoptotic cell death via elevation of intracellular cAMP. Cell viability was not affected upon treatment with dbcAMP suggesting a mode of action independent of IP modulation (Figure 3(c)).

4. Discussion

To address directly the potential role of PGIS in cell survival, we analyzed the effects of PGIS-overexpression in a human breast cancer cell line MCF-7 and of carbaprostacyclin treatment in a human immature T-cell line CCRF-CEM cells. MCF-7 cells overexpressing PGIS showed a significant increase in cell viability when challenged with sulindac and sulindac sulfone. Given that sulindac inhibits prostaglandin-production, and thus PG1 formation, we assume that PG1 generated during the first 24 hours after transfection and prior to the addition of sulindac rendered the cells resistant to the adverse effects of sulindac (sulfone).

Apoptotic cell death of sulindac sulfone treated CCRF-CEM cells exposed to increasing concentrations of carbaprostacyclin was also significantly reduced. To exclude an activation of the classical IP pathway, CCRF-CEM cells were treated with a stable cell permeable cAMP analogue (dbcAMP). The lack of effect of this agent argues against a role of the IP-receptor in the protection against apoptosis.

To the best of our knowledge this is the first study to investigate the expression of PGIS in primary human breast cancer. Data currently available are conflicting. One investigation found no PGIS expression in human lung carcinoma [28], whereas another described a significant reduction of PGIS protein expression in non-small cell lung cancers [29]. However, no correlation with overall patient survival was observed. A more recent study used the same antibody (anti-PGIS) to investigate expression in head and neck squamous

Figure 3: Relationship between PGIS expression and overall survival of 193 patients. The Kaplan-Meier survival curves shown are for subgroups with either low (IRS2) or high (IRS ≥ 3) PGIS expression among all patients under study.
cell carcinoma [30]. Lower PGIS levels were observed in tumor samples than in nontumoral mucosa. Patients who expressed high levels of PGIS in head and neck squamous cell carcinoma had a higher 5-year survival rate than the low PGIS expressing group.

Our present study using an ISH-validated polyclonal antibody [21] on mammary CA also showed weak immunoreactivity in tumors; however, our striking results from retrospective analysis revealed that expression of PGIS is associated with a reduction of patient survival. Although statistical significance was not achieved, the data indicated that patients with a high IRS had a worse prognosis than patients with a low IRS. Given the paucity of data addressing the expression and roles of PGIS and its putative receptor PPAR $\beta/\delta$ in human breast cancer a variety of mechanisms can be postulated that link PGIS expression with a reduction in patient survival. Expression of PGIS in human breast cancer cells might increase their viability in vivo resulting in a less favorable prognosis than for patients who lack PGIS expression in their cancerous cells. This is supported by data that showed that the PPAR $\beta/\delta$ ligand, cPGI, protects HT29 colon cancer cells against cell death in vitro [12]. Likewise, cPGI has been shown to rescue renal medullary interstitial cells from cell death [13]. Finally, activation of PPAR $\beta/\delta$ protected cultured murine keratinocytes against cell death [31]. Importantly, the contention that PGI$_2$ promotes survival of breast cancer cells is compatible with the data from several meta-analyses that demonstrated the chemopreventive effect of NSAIDs on the

Figure 3: Effects of overexpression of PGIS and carbaprostacyclin on cell survival. (a) MCF-7 cells were transiently cotransfected with pCDNA3.1COX-2, together with control vector pCDNA3.1, pCDNA3.1mPGIS, and pCDNA3.1mPGISC441A. Cell viability upon exposure to 150 $\mu$M sulindac for 24 hours was examined by the MTT assay as compared to vehicle-treated controls (0.1% DMSO). (b), (c) Carbaprostacyclin-mediated protection from sulindac sulfone-induced apoptosis. CCRF-CEM cells were treated with 0, 100, and 300 $\mu$M sulindac sulfone in the presence of (b) 0.01–1 $\mu$M carbaprostacyclin or (c) 0.001–10 mM dbcAMP. 24 hours posttreatment caspase-3 activity was measured by cleavage of fluorogenic substrate Ac-DEVD-AMC.
formation of breast cancer in women [8–10]. Inhibition of PGI₂ formation by NSAIDs would neutralize the stimulatory effect of PGI₂ in malignant cells, leading to a reduced incidence of breast cancer.

Alternatively, PGI₂ might actually reduce cell viability as shown by a study in which endogenously expressed PGI₂ promoted apoptosis in human embryonic kidney cells and Caco-2 colon cancer cells [14]. This might indicate that administration of NSAIDs to patients expressing PGIS might actually be disadvantageous. This notion is not supported by epidemiological data, although patient survival has not been stratified in these patients in terms of PGIS expression. These apparently contradictory actions of PGI₂ on cell survival may indicate that its effects are highly dependent on the specific cellular environment.

Despite the fact that the effects of cPGI and PGIS on cell survival are clearly divergent, there is agreement that these effects are not dependent on cAMP generation (and thus activation of IP) but are possibly mediated by PPAR β/δ [14, 17, 31–33]. In contrast to PPAR γ the potential roles of PPAR β/δ have yet to be studied in mammary cancer cells. Two studies addressed the role of PPAR β/δ in colon cancer, one demonstrated that xenografts of null cells (PPAR β/δ−/− cells) derived from the human colon cancer cell line HCT 117 exhibited a significant reduction in tumor formation compared with wild-type HCT 117 cells (PPAR β/δ+/+ cells) [34]. However, the essential role of PPAR β/δ for intestinal tumor formation could not be confirmed in another study using PPAR β/δ knockout mice; polyp size, but not polyp number, was reduced in PPAR β/δ-null mice compared with wild-type mice [35]. More recently, we published data showing impaired tumor-angiogenesis in PPAR β/δ-null mice [36].

Little information exists on the specific role of PGI₃ in human breast cancer. One study showed that elevated levels of the PGI₃ metabolite, 6-keto-PGF₁α, in breast cancer tissue are associated with a more aggressive phenotype [37]. In rats, inhibition of thromboxane synthase by imidazole led to enhanced cancer multiplicity in an N-methyl-N-nitrosourea induced breast cancer model. In contrast, administration of tranilcaptamine, which inhibits PGIS has been shown to reduce cancer multiplicity, indicating that inhibition of this enzyme, but not thromboxane-synthase, might be useful in the chemoprevention of breast cancer [38].

5. Conclusions

We have shown that expression of PGIS in human breast cancer is a negative prognostic factor. Overexpression of PGIS increases cell viability in MCF-7 cells exposed to sulindac and sulindac sulfone and carbaprostacyclin protects against sulindac induced apoptosis in CCRF-CEM cells. The apparent discrepancy to the inverse correlation of PGIS expression and survival in other carcinomas (e.g., head and neck tumors) could not only be explained by hormonal biases. More and larger epidemiological studies in different tumors are needed to analyze the importance of PGIS expression as an independent prognostic factor. The products and molecular targets of PGIS and their implication in mammary tumor formation need to be further elucidated to investigate whether certain subgroups of breast cancer patients show different survival rates in relation to PGIS expression.

Abbreviations

NSAIDs: Nonsteroidal anti-inflammatory drugs
COX: Cyclooxygenase
PGI₂: Prostacyclin
PGIS: Prostacyclin-synthase
HEK293: Human embryonic kidney cells
IP: Adenylate cyclase coupling prostacyclin-receptor
cAMP: Cyclic adenosine monophosphate
PPAR β/δ: Peroxisome proliferator activated receptor β/δ
MCF-7: Human breast cancer cell line
CCRF-CEM: Human T-cell leukemia cell line
PBS: Phosphate buffered saline
ISH: In situ hybridization
IRS: Immunoreactive score
DMEM: Dulbecco’s modified Eagle’s medium
FBS: Fetal bovine serum
RPMI: Roswell Park Memorial Institute
6-Keto-PGF₁α: 6-Keto prostaglandin Flx
cDNA: Complementary deoxyribonucleic acid
GC/MS: Gas-chromatography/mass spectrometry
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diaryl tetrazolium bromide assay
dbcAMP: Dibutryl-cAMP
ir: Immunoreactive.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported by grants from Stiftung P. E. Kempkes (Marburg, Germany) to Martin Kömhoff (19-2001). The authors thank Dr. H. Schweer for GC/MS analysis of prostanoids and Dr. Youfei Guan for provision of a rabbit COX-2 expression vector.

References

[1] M. J. Thun, E. J. Jacobs, and C. Patrono, ”The role of aspirin in cancer prevention,” Nature Reviews Clinical Oncology, vol. 9, no. 5, pp. 259–267, 2012.
[2] W. L. Smith, ”Prostanoid biosynthesis and mechanisms of action,” The American Journal of Physiology: Renal Fluid and Electrolyte Physiology, vol. 263, no. 2, pp. F181–F191, 1992.
[3] M. Komhoff, Y. Guan, H. W. Shappell et al., ”Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas,” The American Journal of Pathology, vol. 157, no. 1, pp. 29–35, 2000.
Referrer: [R. A. Soslow, A. J. Dannenberg, D. Rush et al., “COX-2 is expressed in human pulmonary, colonic, and mammary tumors,” Cancer, vol. 89, no. 12, pp. 2637–2645, 2000.]

[5] M. J. Thun, M. M. Namboodiri, E. E. Calle, W. D. Flanders, and C. W. Heath Jr., “Aspirin use and risk of fatal cancer,” Cancer Research, vol. 53, no. 6, pp. 1322–1327, 1993.

[6] R. E. Harris, G. A. Alshafie, H. Abou-Issa, and K. Seibert, “Chemosuppression of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor,” Cancer Research, vol. 60, no. 8, pp. 2101–2103, 2000.

[7] K. M. Egan, M. J. Stampfer, E. Giovannucci, B. A. Rosner, and G. A. Colditz, “Prospective study of regular aspirin use and the risk of breast cancer,” Journal of the National Cancer Institute, vol. 88, no. 14, pp. 988–993, 1996.

[8] S. A. Khuder and A. B. Mutgi, “Breast cancer and NSAID use: a meta-analysis,” British Journal of Cancer, vol. 84, no. 9, pp. 1188–1192, 2001.

[9] B. Takkouche, C. Regueira-M´endez, and M. Etminan, “Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis,” Journal of the National Cancer Institute, vol. 100, no. 20, pp. 1439–1447, 2008.

[10] Y.-S. Zhao, S. Zhu, X.-W. Li et al., “Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis,” Breast Cancer Research and Treatment, vol. 117, no. 1, pp. 141–150, 2009.

[11] E. K.-H. Han, N. Arber, H. Yamamoto et al., “Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines,” Breast Cancer Research and Treatment, vol. 48, no. 3, pp. 195–203, 1998.

[12] T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999.

[13] C.-M. Hao, R. Redha, J. Morrow, and M. D. Breyer, “Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21341–21345, 2002.

[14] T. Hatae, M. Wada, C. Yokoyama et al., “Site-directed mutagenesis of PPARδ in human colon cancer,” The American Journal of Physiology, vol. 273, no. 1, pp. F18–F26, 1997.

[15] K. K. Wu and J.-Y. Liou, “Cellular and molecular biology of prostacyclin synthase,” Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 45–52, 2005.

[16] L. Erment, C. Dierkes, and M. Erment, “Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors,” Clinical Cancer Research, vol. 9, no. 5, pp. 1604–1610, 2003.

[17] M.-C. Cathcart, S. G. Gray, A.-M. Baird et al., “Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer,” Cancer, vol. 117, no. 22, pp. 5121–5132, 2011.

[18] M. Camacho, Z. Piñeiro, S. Alcolea et al., “Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy,” The Journal of Pathology, vol. 235, no. 1, pp. 125–135, 2015.

[19] N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of PPAR-β/δ in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 4, pp. 3263–3277, 2001.

[20] H. Lim, R. A. Gupta, W.-G. Ma et al., “Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ,” Genes & Development, vol. 13, no. 12, pp. 1561–1574, 1999.

[21] B. H. Park, B. Vogelstein, and K. W. Kinzler, “Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2598–2603, 2001.

[22] H. E. Marin, M. A. Peraza, A. N. Billin et al., “Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis,” Cancer Research, vol. 66, no. 8, pp. 4394–4401, 2006.

[23] J. M. Peters, P. Yao, and F. J. Gonzalez, “Targeting peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) for cancer
chemoprevention,” *Current Pharmacology Reports*, vol. 1, no. 2, pp. 121–128, 2015.

[36] S. Müller-Brüsselbach, M. Könhoff, M. Rieck et al., “Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice,” *The EMBO Journal*, vol. 26, no. 15, pp. 3686–3698, 2007.

[37] G. M. Laekeman, I. B. Vergote, G. M. Keersmaekers et al., “Prostacyclin and thromboxane in benign and malignant breast tumours,” *British Journal of Cancer*, vol. 54, no. 3, pp. 431–437, 1986.

[38] D. L. McCormick, A. M. Spicer, and J. L. Hollister, “Differential effects of tranlynlypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets,” *Cancer Research*, vol. 49, no. 12, pp. 3168–3172, 1989.